Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 3/20 | 0.35 |
| ▸ | ESR1 | P03372 | 9/20 | 0.34 |
| ▸ | BRD4 | O60885 | 5/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.32 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11899128 | 1.00 | NSD3 (0.38) | NSD3HSP90AB1ERN1ESR1BRD4 | |
| SCHEMBL20913310 | 1.00 | NSD3 (0.38) | NSD3HSP90AB1ERN1ESR1BRD4 | |
| SCHEMBL11898859 | 0.90 | ESR1 (0.40) | NSD3HSP90AB1ERN1ESR1BRD4 | |
| SCHEMBL1682293 | 0.90 | ESR1 (0.40) | NSD3HSP90AB1ERN1ESR1BRD4 | |
| SCHEMBL1682294 | 0.90 | ESR1 (0.40) | NSD3HSP90AB1ERN1ESR1BRD4 | |
| SCHEMBL11898569 | 0.88 | ERN1 (0.43) | NSD3HSP90AB1ERN1ESR1BRD4 | |
| SCHEMBL11899875 | 0.84 | ESR1 (0.34) | ESR1ESR2 | |
| SCHEMBL1682482 | 0.84 | ESR1 (0.34) | ESR1ESR2 | |
| SCHEMBL1682480 | 0.84 | ESR1 (0.34) | ESR1ESR2 | |
| SCHEMBL11899874 | 0.84 | ESR1 (0.34) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2486018-B1 | SUBSTITUTED PYRAZOLES AS ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2019-04-24 | — | — | EP | claimed |
| US-8921402-B2 | Substituted pyrazoles as estrogen receptor ligands | KARO BIO AB (SE) | 2014-12-30 | — | — | US | claimed |
| US-20140128435-A1 | SUBSTITUTED PYRAZOLES AS ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2014-05-08 | — | — | US | claimed |
| US-8653112-B2 | Substituted pyrazoles as estrogen receptor ligands | KARO BIO AB (SE) | 2014-02-18 | — | — | US | claimed |
| US-20120202853-A1 | SUBSTITUTED PYRAZOLES AS ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2012-08-09 | — | — | US | claimed |
| US-11628146-B2 | Estrogen receptor ligand treatment for neurodegenerative diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-04-18 | — | — | US | disclosed |
| US-20210008002-A1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-01-14 | — | — | US | disclosed |
| US-10758496-B2 | Estrogen receptor ligand treatment for neurodegenerative diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-01 | — | — | US | disclosed |
| EP-2486018-B1 | SUBSTITUTED PYRAZOLES AS ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2019-04-24 | — | — | EP | disclosed |
| US-20170304216-A1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-10-26 | — | — | US | disclosed |
| WO-2017031276-A1 | METHODS OF PROVIDING NEUROPROTECTIVE THERAPY RELATED TO ADMINISTERING AN ESTROGEN RECEPTOR BETA LIGAND | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008002-A1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | ESR2, ESRRG, ESR1 | NSD3 3494/4885HSP90AB1 1317/4885ERN1 994/4885 |
| US-20120202853-A1 | SUBSTITUTED PYRAZOLES AS ESTROGEN RECEPTOR LIGANDS | GPER1, ESR1, ESRRA | NSD3 881/4885HSP90AB1 3818/4885ERN1 690/4885 |
| US-20170304216-A1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | ESR2, ESRRG, ESR1 | NSD3 3494/4885HSP90AB1 1317/4885ERN1 994/4885 |
| US-11628146-B2 | Estrogen receptor ligand treatment for neurodegenerative diseases | ESR2, ESRRG, ESR1 | NSD3 3494/4885HSP90AB1 1317/4885ERN1 994/4885 |
| US-20140128435-A1 | SUBSTITUTED PYRAZOLES AS ESTROGEN RECEPTOR LIGANDS | GPER1, ESR1, ESRRA | NSD3 881/4885HSP90AB1 3818/4885ERN1 690/4885 |
| US-10758496-B2 | Estrogen receptor ligand treatment for neurodegenerative diseases | ESR2, ESRRG, ESR1 | NSD3 3494/4885HSP90AB1 1317/4885ERN1 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.